Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. - Wikidata - awgldk - TriplyDB

Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine.

Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine.

http://www.wikidata.org/entity/Q33909187

about

Effect of vaccine administration modality on immunogenicity and efficacy.Contribution of vaccines to our understanding of pneumococcal disease.Panel 6: Vaccines.The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine.GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis.Identification of protective pneumococcal T(H)17 antigens from the soluble fraction of a killed whole cell vaccine.The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens Next generation pneumococcal vaccines Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.Vaccines and global health.Infection with conditionally virulent Streptococcus pneumoniae Δpab strains induces antibody to conserved protein antigens but does not protect against systemic infection with heterologous strains.Immunization with a Double-Mutant (R192G/L211A) of the Heat-Labile Enterotoxin of Escherichia coli Offers Partial Protection against Campylobacter jejuni in an Adult Mouse Intestinal Colonization Model.Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system.T(H)17-Mediated Protection against Pneumococcal Carriage by a Whole-Cell Vaccine Is Dependent on Toll-Like Receptor 2 and Surface Lipoproteins.Characterization of Th17 responses to Streptococcus pneumoniae in humans: comparisons between adults and children in a developed and a developing country.Mucosal vaccine adjuvants update.A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.A live attenuated Salmonella Enteritidis secreting detoxified heat labile toxin enhances mucosal immunity and confers protection against wild-type challenge in chickens.Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.Rationale and prospects for novel pneumococcal vaccines.Impaired innate mucosal immunity in aged mice permits prolonged Streptococcus pneumoniae colonization.Serotype-independent pneumococcal vaccines.Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.Immune ageing and susceptibility to Streptococcus pneumoniae.Mucosal vaccine delivery: Current state and a pediatric perspective Regionally compartmentalized resident memory T cells mediate naturally acquired protection against pneumococcal pneumonia.A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.Mucosal vaccination promotes clearance of Streptococcus agalactiae vaginal colonization.Promises and pitfalls of live attenuated pneumococcal vaccines.Should Pneumococcal Vaccines Eliminate Nasopharyngeal Colonization?Structural Characterization and Physicochemical Stability Profile of a Double Mutant Heat Labile Toxin Protein Based Adjuvant.Development of pneumococcal vaccines over the last 10 years.Evaluation of the role of stat3 in antibody and TH17-mediated responses to pneumococcal immunization and infection using a mouse model of Autosomal Dominant Hyper IgE Syndrome.Recent approaches in whole cell pneumococcal vaccine development: a review study.Serotype-independent protection against pneumococcal infections elicited by intranasal immunization with ethanol-killed pneumococcal strain, SPY1.The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT

P2860

Q27692376-63251268-E6E2-4E4D-B7CC-D6FB8842731D Q30406750-4C9BDCFE-E87A-4660-9C05-B5D097DA7840 Q33644678-DC4EDD83-FB14-416B-BBAC-6A19CBA00E31 Q34270342-8EB1F51B-B77A-425F-9E07-B030C0710C36 Q34298079-E8EF15B9-448C-4088-9E50-762FC98FC003 Q34310321-470DCE79-D4E8-4502-9B14-1A93EDD986F4 Q34385066-EAE02C89-C376-4A92-9E4D-D9B584BD73B0 Q34532223-919C40D3-D695-4959-900A-3A5B04D2C924 Q35028495-946F74B8-D28A-4A5E-B7EF-7BE45A43B8A9 Q35066293-726FFB8F-EE3B-4ACB-A40E-D9BDFC6E5F87 Q35137116-5D6205BB-23F7-40D4-A7CC-927F1B9E93CE Q35598060-6D63187A-4644-493B-BF9E-C329921E7B9A Q35833473-F7FE9E5A-16A8-437D-8395-227990462FC6 Q35844906-94F7FF04-92AB-4CC0-892F-0E4CDD74B8D3 Q35886523-57C8687E-0AD6-4AC6-912D-75E7805C1581 Q35902005-F9AF211F-B71A-4C1A-9B5B-33DF74DA91D6 Q36013814-2DB00D56-F5E9-4616-A5B6-924C77A1DAA3 Q36758075-DC417AB8-9CE7-42C3-B1F1-C4B92EB20D8D Q36826907-7F231049-EA21-460C-9909-B8F032008795 Q36969236-73351FD6-C3AA-46BC-89E7-E5612E5F7A14 Q37032264-0200BF8E-B9E8-4AA4-B020-86F4655933B5 Q37309218-03732066-099F-42D6-B7A3-9CE836618BC5 Q37336016-1A0618A9-B478-42A5-A084-06787124CB84 Q38069943-7E947C52-DC3E-49EC-BF75-8CCC7A9B0E8E Q38335733-6AC889FC-0321-4507-B9EB-C6682BEA0C37 Q38608479-6386CD77-80B8-4B23-B926-E2B00F792BE5 Q38727453-F2AB3BF9-5EC7-424B-AE28-835C481F7008 Q40209420-AD9DA65C-9CE9-4FCB-BF7B-8AD05342982C Q40291567-D34323B9-50EB-4762-9DBC-33F423089846 Q40344808-778E6FD7-A668-48CC-B96C-A271BF3831B1 Q41612508-C032242E-8C56-4B34-AA55-666637A9A019 Q42739652-2B4B55E3-EBB6-4617-8EB5-6BA4EE0CCA61 Q47305690-7B88B70C-289A-4EFC-A8FD-C076FE9E11AB Q47658958-5BA06131-5A03-4361-93CD-7D4444FC283D Q49791367-1CCAEFB5-DB96-4D5C-8CC7-49844C8846E4 Q50305151-A4932C2A-3FF3-46CD-A2B1-19D7E0297F8B Q51744963-CA80ED3A-FF63-4420-A115-F8974ABE6E22 Q57945015-1CDBC4D8-40F1-492C-9EEB-8B84972FF646

P2860

Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine.

http://www.wikidata.org/entity/Q33909187

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Options for inactivation, adju ...... eumococcal whole-cell vaccine.

@ast

Options for inactivation, adju ...... eumococcal whole-cell vaccine.

@en

type

label

Options for inactivation, adju ...... eumococcal whole-cell vaccine.

@ast

Options for inactivation, adju ...... eumococcal whole-cell vaccine.

@en

prefLabel

Options for inactivation, adju ...... eumococcal whole-cell vaccine.

@ast

Options for inactivation, adju ...... eumococcal whole-cell vaccine.

@en

P1433

Q33909187-AEF9F082-7E1E-4921-B5FC-6FC0E6C48BAC

P1476

Q33909187-A4E9F8BD-4C0A-4796-86CB-3E497ABCA36C

P2093

Q33909187-21AD5854-7584-4ACF-B92C-4023B6D92D05

Q33909187-3A101280-58B6-4DDF-B1EA-DBE8042D54D8

Q33909187-43B372C9-E3AE-41FC-A63D-193820671192

Q33909187-4812AF49-122F-462B-8ABF-81E1CCF6326E

Q33909187-5203B4EA-8F20-492F-88DB-92DDBBE75B0C

Q33909187-59B39376-B093-4948-B1A1-0BF864EE1894

Q33909187-5AC80F34-ECA8-449A-A4F0-F1A4310B9443

Q33909187-7F077010-0339-4695-B6C6-E02B56F48FDB

Q33909187-B974E936-E5CD-42A2-B498-F13FEA690191

Q33909187-C122BFC6-15DD-4D29-8E29-C7269DB631F0

P2860

Q33909187-0385566D-301D-4516-97C9-881A04181FB9

Q33909187-0CAF6AA2-3A3D-423A-9CB3-1F6DB6F8BF23

Q33909187-2303D4AA-4FFB-4634-B550-A309C890F0AC

Q33909187-25CCBF81-940B-4841-A8F0-33CA0917C083

Q33909187-29BD6F51-2FBF-46B0-B5F5-A1FEDC45F1B5

Q33909187-2CFAE236-02A4-4016-AFCE-24DB28EBDE41

Q33909187-35560464-8A0C-4649-A986-B80ECAB6E30C

Q33909187-3ABEAF81-3A69-4644-BC3C-6A4055D7496E

Q33909187-3F4B55C7-B842-40A1-ABDA-DC7D096E41C6

Q33909187-43B852F1-0928-43BC-BE3C-7002483CA8A8

P304

Q33909187-A62E7EDA-3E7A-4201-8507-5D22470452DC

P31

Q33909187-F222FF26-2F5F-4ACB-9B2C-4B246E1D3781

P356

Q33909187-A055D1B8-6233-44AE-A6C0-51DB12E42B4B

P433

Q33909187-72E96470-4959-4474-95B2-B01852EC53C2

P478

Q33909187-90264579-8040-492E-A5E6-25E7830335D3

P577

Q33909187-CD704E93-F3EA-48D0-9E85-AFAE7DC464E9

P698

Q33909187-5881499C-13D0-41C8-B4B2-A0EDA64EBDFA

P932

Q33909187-B461FA63-13BD-4614-8BF4-D54711CF29B8

P356

P1433

Clinical and Vaccine Immunology

P1476

Options for inactivation, adju ...... eumococcal whole-cell vaccine.

@en

P2093

Amit Srivastava

http://www.w3.org/2001/XMLSchema#string

Andrea Tate

http://www.w3.org/2001/XMLSchema#string

Claudette M Thompson

http://www.w3.org/2001/XMLSchema#string

George Robertson

http://www.w3.org/2001/XMLSchema#string

Jean-François Maisonneuve

http://www.w3.org/2001/XMLSchema#string

Jee Look

http://www.w3.org/2001/XMLSchema#string

John D Clements

http://www.w3.org/2001/XMLSchema#string

Mark Alderson

http://www.w3.org/2001/XMLSchema#string

Porter W Anderson

http://www.w3.org/2001/XMLSchema#string

Puja Yadav

http://www.w3.org/2001/XMLSchema#string

P2860

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies

Interleukin-17A mediates acquired immunity to pneumococcal colonization

Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin subunit B

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.

A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae

CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization.

An rpsL cassette, janus, for gene replacement through negative selection in Streptococcus pneumoniae.

P304

1005-1012

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/CVI.00036-10

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20427625

http://www.w3.org/2001/XMLSchema#string

P932

2884428

http://www.w3.org/2001/XMLSchema#string